In the previous three communications on the mechanism of action of sulfanilamide, Sevag and Shelburne (1) reported that this drug primarily blocked bacterial cell respiration in the absence as well as in the presence of active growth. The inhibition of aerobic and anaerobic respiration resulted in the proportional inhibition of growth under the conditions used. p-Aminobenzoic acid often reversed partly or completely the inhibition of respiration by sulfanilamide.
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(Received for publication, March 28, 1942) In the previous three communications on the mechanism of action of sulfanilamide, Sevag and Shelburne (1) reported that this drug primarily blocked bacterial cell respiration in the absence as well as in the presence of active growth. The inhibition of aerobic and anaerobic respiration resulted in the proportional inhibition of growth under the conditions used. p-Aminobenzoic acid often reversed partly or completely the inhibition of respiration by sulfanilamide.
On the basis of the above findings and those of others reviewed previously (1), a theory correlating the drug action with the similarity of chemical structures of the drugs and the coenzymes was formulated. It was stated that the chemotheraPeutic substances which have structural similarity to the whole, or part of the coenzyme molecules may combine specifically with the protein carrier of the respiratory enzymes--the result being the displacement of the coenzymes by the drug and the formation of an inactive "enzyme-analogue" or the formation of a hypothetical "drug-protein-coenzyme" complex. These being incapable of oxidizing glucose, bacterial respiration and growth are inhibited. In advancing this theory reservations were made to account for the activity of such drugs as do not possess structural similarity with the known coenzymes. In such cases mutual affinity between the drug and the specific enzyme proteins was considered as a possible determining factor.
In accordance with the above theory sulfapyridine, for example, with its pyridine ring was mentioned as a potential competitor of cozymase I and II, and sulfathiazole (likewise sulfadiazine) of cocarboxylase. These coenzymes are present in the respiratory systems of most living cells. They, therefore, offer the first point of attack in determining which link in the chain of reactions associated with the metabolism of glucose is affected most by a given sulfonamide drug.
Bacterial and yeast carboxylase systems were chosen for this study as one of the means to test and corroborate the implications of the above theory. The decarboxylation of pyruvic acid by carboxylase is of almost universal occurrence in living cells. This reaction, carried out under anaerobic conditions, is principally a one-step reaction, and is relatively free from the interference of side or parallel reactions. The effect of the drugs will be, therefore, directly on the carboxylase system. To obtain clearer insight into the relative importance of various rings and radicals in the molecules of the drugs in inhibiting the carboxylase system, the widely used sulfonamide drugs, their homologues, and their simple components were studied comparatively.
The Enzyme Systems Studied
DETERMINATION OF THE CARBOXYLASE ACTIVITY OF BACrEI~IA AND YEASTS.--Pneumococcus Type I, Streptococcus pyogenes (C203M), Staphylococcus aureus, Escherichia coli, and brewer's and baker's yeast were studied to determine the optimal conditions of their carboxylase activity. The experiments were carried out anaerobically in an atmosphere of 95 per cent nitrogen and 5 per ccnt COs in the presence of sodium pyruvate solution. The CO2 evolved was measured manometricaUy with a Barcroft-Warburg set-up. All of the gas evolved was absorbable if KOH was placed in the inset tube of the vessel, showing the evolved gas to be C02.
Pneumococcus Type /.--Suspensions of Pneumococcus Type I, washed and unwashed, grown for 4 and 16 hours in serum broth, in the presence and absence of catalase (to eliminate H2Os formed during growth), were tried out in three separate experiments at pH 6. In no case did decarboxylation of pyruvate takc phce. In parallel experiments the addition of I, 5, I0, and 1007 of cocarboxylase and of 0.1 rag. of Mg did not produce any activity. Decarboxylation of pyruvic acid by pneumococci (2) evidentally takes place by a different route and will be discussed later.
Streptococcus pyogenes.--In contrast, similar experiments with Streptococcus pyogenes (C203M) grown for 16 hours in serum broth showed a residual carboxylase activity. This activity was markedly augumented by the addition of cocarboxylase; 33 c.mm. of COs were evolved in the absence of cocarboxylase while 124 c.mm. of CO2 were evolved when 100-}, of cocarboxylase were added. In a second experiment a dense suspension of streptococci grown for 16 hours did not show any activity in the presence of 0.0517 ~r pyruvate, but the addition of 25"}, of cocarboxylase caused the evolution of 72 c.mm. of COs within 150 minutes. An increase of 50 to 100-y of cocarboxylase did not improve this activity. The activity being too small, this organism was not further employed in the present study.
Staphylococcus aureus. Curves IA, IIA, and IIIA represent the activity of 14.4, 7.2, and 3.6 rag., respectively, of staphylococci dried from the frozen state. study of the fresh and the corresponding dried samples of equal weights (Fig. 1) show that on drying from the frozen state staphylococci experience practically no loss of carboxylase activity. The addition of 1 to 10~, of cocarboxylase to the reaction system did not increase the activity of staphylococci.
Optimal Carboxylase Activity of Dried Stapkylococci.--Experiments were carried out to determine the optimal activity as a function of pH and as a function of concentration of substrate. The results are given in Table I .
Removal and Restoration of Carboxylase Activity of Staphylococcus aureus.--To test
whether the COs evolved was due to carboxylase the following experiments were carried out. Fresh suspensions or suspensions of staphylococci dried from the frozen state were treated according to the method of Lohmann and Schuster (3) to remove cocarboxylase. Pure cocarboxylase (Merck) was then added and the de- The experiments were carried out at pH 7.16 in consideration of the inhibition experiments with drugs which have greater solubility at this pH than at the pH of optimal activity. The reaction system was identical with that used in pH experiments except for varying quantifies of pyruvate. On the other hand, if the staphylococci are dried from the frozen state and then washed with either ~/10 Na2HPO4 or 0.85 per cent NaC1 the activity is reduced about 50 per cent (Table II) z The aerobic metabolism of pyruvic acid in Staph. aureus has previously been investigated (4, 5) . In connection with the present study the reader is referred to a paper by Krebs (6) (7) 
Inhibition of Carboxylase by Sulfonamide Drugs and Their Derivatives
The inhibitory effect of sulfonamide drugs and derivatives on the carboxylase activity of Staph. aureus, E. coli, baker's and brewer's yeast, and a carboxylase lactate and acetate, and this reaction is the preferential one. Studying this reaction aerobically he found that 0.1 ~ of pyruvate consumed 328 c.mm. 02, and anaerobically evolved 249 c.mm. CO2 within a 95 minute period. In our experiments 0.1 z~ of pyruvate consumed 52 c.mm. O2 and evolved 651 c.mm. total CO2 (free and bound as NaHC03), within a 120 minute period. Anaerobically 0.1 M pyruvate evolved 430 c.mm. CO2. In parallel experiments, the oxygen consumed by 0.1 ~ pymvate was 52 c.mm. in contrast to 286 c.mm. O2 consumed by 0.05 ~r lactate. These results show that the dismutation of pyruvate to lactate progresses at a very much slower rate than the decarboxylafion of pyruvate. Within a 2 hour period, under the conditions of our experiments, not more than 10-20 per cent lactate could have been formed. This small percentage of dismutation of pyruvie acid to lactic acid does not introduce an error into the interpretation of the results of the present study from the point of view of the action of sulfonamides on the activity of earboxylase.
The discrepancy between our results and those of Krebs is of quantitative nature and not one of principle. This is no doubt due to the difference of strains of Stapk. aureus used, conditions of culture, and of experiments. Such differences in bacterial metabolic activity have been reported frequently (2, 5). 
** I n a c o m p a r a t i v e s t u d y t h e i n h i b i t i o n of t h e c a r b o x y l a s e a c t i v i t y of Stapkylococcus aureus a t t h e e n d of 120 m i n u t e s w a s 50 p e r c e n t w i t h s u l f a t h i a z o l e , 15.8 p e r c e n t w i t h 2 -a m i n o t h i a z o l e ; n o effect w a s o b s e r v e d w i t h 2 -a m i n o p y r i m i d i n e or w i t h 2 -a m i n o p y r i d i n e .
T h e effect o n E. colt w a s 46.3, 37.4, 4.1, a n d 10.
p e r c e n t i n h i b i t i o n respectively. T h e i nh i b i t o r y effect on y e a s t c a r b o x y l a s e a c t i v i t y w a s 42, 6.4, 7.4, a n d 3 p e r c e n t r e s p e c t i v e l y . T h e m o l a r i t y of all d r u g s w a s 5.52 X 10 4 . F r e s h 16 h o u r c u l t u r e s . § S m a l l e r values o b t a i n e d w i t h 5 m g of y e a s t ; l a r g e r v a l u e s o b t a i n e d w i t h 10 m g of y e a s t .
H Dialyzed• 811 preparation from brewer's yeast was studied. In these experiments the optimal conditions of carboxylase activity as described above were employed.
Sparing solubility of some of these substances limited the maximum concentration to 1.38 X 10 -~ ~. Where it was possible other drugs were compared at a concentration of 5.52 X 10 -3 ~ as weU, and sulfanilamide up to 27.6 X 10 -3 ~s. The drugs were dissolved in a saline-phosphate mixture of pH 7.16 (90 cc. saline + 10 cc. M/15 phosphate buffer), heated to 56°C. if necessary.
The reaction system contained, in a volume of 5.8 cc., the drug as indicated in Table III , the suspension of organisms, 0.1 rag. of Mg as magnesium chloride and 26.4 mg. of pyruvic acid (0.0517 ~) neutralized to pH 7.1, and a final phosphate buffer concentration of ~/125. Pyruvate in a volume of 0.5 cc. was introduced into the system from the side arm after temperature equilibration of the system. Although the optimal carboxylase activity takes place at pH 6.0, a system at pH 7.10 was used in consideration of the greater solubility of the drugs at this pH. The duration of the experiments was 120 minutes. The dry weight of 
Removal of Sulfathiazole from Sulfathiazole-Treated Staphylococcus aureus
In the previous communication it was suggested that the drugs either combine with the enzyme system forming a "drug-protein-coenzyme" complex or displace coenzyme forming a "drug-protein" enzyme analogue.
The result of the experiment, given in Table IV , does not give evidence of displacement of cocarboxylase; the drug may possibly have formed a hypothetical reversible "drug-protein-cocarboxylase" complex. A fresh 16 hour culture of Staph. aureus was washed with ~r/15 phosphate buffer of pH 7.16. A dense 2 cc. suspension was treated with 30 cc. of 5.52 X 10 -3 x~ sulfathiazole solution for 35 minutes at 37.5°C. The suspension was then centrifuged and twice washed with phosphate buffer. A control containing no sulfathiazole was given identical treatment. The COs production was then measured in the Barcroft-Warburg set-up.
DISCUSSION
Suspensions of Streptococcus pyogenes exercised weak carboxylase activity. The addition of 25-100 "r of cocarboxylase (Merck's) to the reaction system ac-celerated carboxylase activity several fold. It appears that the carboxylase of the suspension of this organism is impaired in some manner, or perhaps it dissociates more readily than in other cells, and thereby the cocarboxylase is lost.
Barron and Jacobs (8) state that in the absence of oxygen pyruvic acid is split by hemolytic streptococci into acetic acid and formic acid:
CHsCOCOOH + H20 ~ CI-IsCOOH + HCOOH Our findings show definitely that the anaerobic metabolism of pyruvic acid involves also its decarboxylation by streptococcal carboxylase:
As far as we know this fact has not been observed previously.
The suspensions of Pneumococcus Type 1 did not exercise activity even in the presence of 1-100 7 of cocarboxylase. The metabolism of pyruvic acid by pneumococci must therefore take place by a different mechanism. Sevag (2) previously showed that hydrogen peroxide formed from the oxidation of glucose and lactic acid reacts instantaneously with the pyruvic acid resulting simultaneously, and produces acetic acid, carbon dioxide, and water. In the absence of carboxylase in the pneumococcic cells this appears to be the principle mechanism of the decarboxylation of pyruvic acid.
The production of COs from the anaerobic metabolism of pyruvic acid in Staph. aureus, E. coli, brewer's yeast, and baker's yeast and a carboxylase preparation from brewer's yeast is inhibited by sulfonamide drugs to varying degrees. The results are given in Table III .
The results clearly show that the thlazole group is the most effective inhibitor of staphylococcal carboxylase; similarly of the E. coli carboxylase. Yeast carboxylase and carboxylase prepared from yeast are inhibited by the substances containing pyrimidine, pyridine, and thlazole rings to similar degree, except in sulfamethyldiazine which is completely ineffective on all the organisms studied. At 1.38 X 10 -3 ~ concentration, 2-aminopyrimidine and 2-aminothiazole show practically no inhibition of Staph. aureus and E. coli carboxylases. An increase in concentration of 2-aminopyrimidine to 5.52 X 10 --8 ~r shows no increase in inhibition. However, an increase of 2-aminothlazole to 5.52 × 10 --3 concentration results in an inhibition three to five times as great, indicating a definite affinity between this thlazole ring and the enzyme system. With yeast an increase in molarity resulted in an increase in inhibition by both substances. (See also footnote ** to Table III. )
Of all the substances tested, 2-sulfanilamido-5-ethyl-4-thlazolone appears to be the most effective inhibitor on E. coli and Stapk. aureus. Its effect on yeast, however, is about equal to that of sulfathiazole. It is also interesting to note that a methyl group on sulfadiazine obviates its inhibitory effect nearly completely, whereas a methyl group on sulfathiazole does not lessen the inhibitory effect on Staph. aureus and E. coli, and somewhat increases this effect on yeast.
While the inhibiting effect of 27.6 X 10 -~ M sulfanilamide on Stapk. aureus is negligible, it inhibits E. coli, yeast, and carboxylase, respectively, 41, 56.3, and 62 per cent. This shows that enzyme proteins in these organisms exhibit different affinities towards this substance.
According to Buchman, Heegard, and Bonner (9) thiazole pyrophosphate markedly inhibits the activity of cocarboxylase. Neither thiazole, nor pyrophosphate alone exercised any inhibiting effect in their experiments. The union between thiazole pyrophosphate and carboxylase protein is stated to be through the pyrophosphate group which is common to both the cocarboxyiase and the inhibitor. In our study, we did not find the presence of pyrophosphate group an essential factor in demonstrating the inhibitory effect of the sulfonamides and the thiazole ring on the enzyme system.
A comparison of the chemical structures of the drugs containing the pyrimidine and thiazole rings with the chemical structure of cocarboxylase containing both rings may help to evaluate the degree of inhibition one can expect them to exercise on the carboxylase system. The results in Table III permit us to state that thiazole groups exercise a high degree of specific inhibition on the Stapk. aureus and the E. coli systems. On the other hand, the carboxylase system of yeast and a carboxylase preparation from yeast are equally affected by sulfonamides containing pyrimidine, thiazole, and pyridine rings; sulfamethyldiazine, however, is completely ineffective on all the organisms studied. Sulfanilamide appears to possess the smallest affinity for the enzyme system. However, it is a potential inhibitor, and this potentiality demonstrates its power when rings such as pyridine, pyrimidine, and thiazole are attached to the sulfamido group.
It is interesting in this connection to refer to the observation made by Rammelkamp and Jewell (10) on the effect of sulfadiazine and sulfathiazole on the growth of Stapk. aureus. They found that sulfathiazole added to blood exercised a somewhat greater effect than sulfadiazine against staphylococci. Moreover, the action of sulfathiazole becomes manifest at lower concentrations. When the drugs were administered orally, sulfathiazole invariably produced an increase in the bactericidal action of the blood as great or greater than sulfadiazine, even though the concentration of sulfadiazine was twice that of sulfathiazole. Similarly the results obtained by Straus, Dingle, and Finland (11) show that sulfathiazole is about 4 times as effective as sulfadiazine, 8 times as effective as sulfanilamide, and 5-6 times as sulfapyridine on the growth of Staph. aureus. Their comparative studies (11) on the inhibition of the growth of E. coli with these drugs yielded similar results. In this case, sulfathiazole was 5 times as effective as suffapyridine, twice as effective as sulfadiazine and 40-50 times as sulfanilamide.
The results given by us in Table III O~ drugs on the inhibition of growth and the inhibition of the metabolism of pyruvic acid seems to point to a possible direct relationship, emphasizing the importance of pyruvic acid metabolism during the multiplication of these organisms. On the other hand the failure to find carboxylase in pneumococci suggests that sulfathiazole may inhibit some other enzyme than carboxylase in these microorganisms. If the sulfonamide drugs exercise their inhibitory effect on enzymes in part by virtue of the similarity of their structure to the coenzyme molecule, as the results presented in this study appear to indicate, then another group of biologically active substances, such as vitamins and vitamin derivatives, structurally related to both the drugs and the coenzymes, might be expected to modify the inhibitory action of the drugs. The present study is being followed by an investigation of this problem.
Since cozymases, like carboxylases, are universally present in the respiratory enzyme system, the possible relation of the action of sulfonamides to the structural similarity existing between them and the cozymases must likewise be investigated. The result of such an investigation will no doubt be significant from the point of view of the theory concerning the mechanism of antibacterial drug action. 
SUMMARY
The inhibiting effects of sulfonamide drugs and their derivatives on the anaerobic decarboxylation of pyruvic acid by Staphylococcus aureus, Escherichia coli, baker's and brewer's yeast, and a carboxylase preparation from brewer's yeast have been investigated. These drugs are: sulfanilamide, sulfapyridine, sup fadlazine, sulfamethyldiazine, sulfathiazole, sulfamethylthlazole, sulfanilamido-5-ethyl-4-thiazolone, 2-aminopyrimidine, 2-aminothiazole, and 2-aminopyridine.
The sulfathiazole ring appears to exercise decidedly greater specific inhibiting effect on the carboxylases of Staph. aureus and E. coli. The inhibiting effect on yeast carboxylase is non-differentiable among all the substances tried, except sulfamethyldiazine which is completely ineffective on the carboxylases of the organisms studied.
The specific inhibitory effect of sulfathlazole on the carboxylases of Staph. aureus and E. coli in comparison to sulfanilamide, sulfapyridine, and sulfadiazine is in harmony with in vivo and in vitro experimental results of other investigators.
